|Bid||108.00 x 1100|
|Ask||112.66 x 1200|
|Day's Range||111.64 - 113.26|
|52 Week Range||75.58 - 127.79|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||11.56|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||144.44|
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Wedbush PacGrow Healthcare Virtual Conference.
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.